Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Alexion Pharma takes over Taligen for $111mm up front

Executive Summary

Rare disease drug company Alexion Pharmaceuticals Inc. is paying $111mm in cash up front for privately held Taligen Therapeutics Inc. (inflammatory diseases). Shareholders of the acquired firm are also eligible for $367mm in earn-outs tied to clinical efficacy and approval milestones in the US and EU for up to six Taligen drug candidates.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Contract
    • Acquisition of Private Biotech
    • Intra-Biotech Deal
    • Includes Earnout
    • Payment Includes Cash
    • Full Acquisition

Related Companies